[
    {
        "unnamed:_1":0,
        "gene_name":"RB1",
        "genomic_position":"13:48877911-49056122(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Alpelisib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:25002028"
    },
    {
        "unnamed:_1":1,
        "gene_name":"RB1",
        "genomic_position":"13:48877911-49056122(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Alpelisib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:25002028"
    },
    {
        "unnamed:_1":2,
        "gene_name":"RB1",
        "genomic_position":"13:48877911-49056122(+)",
        "cds_mutation":"PHOSPHORYLATION",
        "aa_mutation":"p.PHOSPHORYLATION",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Resistance",
        "therapies":"Alpelisib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:25002028"
    },
    {
        "unnamed:_1":3,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"unspecified_and_ERBB2_unspecified",
        "aa_mutation":"unspecified_and_ERBB2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":4,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"unspecified_or_BRCA2_unspecified",
        "aa_mutation":"unspecified_or_BRCA2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":5,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":6,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"unspecified_or_BRCA2_unspecified",
        "aa_mutation":"unspecified_or_BRCA2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":7,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"unspecified_or_BRCA2_unspecified",
        "aa_mutation":"unspecified_or_BRCA2_unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":8,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "aa_mutation":"unspecified_or_BRCA2_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":9,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "aa_mutation":"unspecified_or_BRCA2_unspecified_or_PALB2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":10,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
        "aa_mutation":"unspecified_or_BRCA2_unspecified_or_CHEK2_unspecified_or_PALB2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":11,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":12,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":13,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"Loss-of-function",
        "aa_mutation":"Loss-of-function",
        "disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":14,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"Loss-of-function",
        "aa_mutation":"Loss-of-function",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":15,
        "gene_name":"BRCA1",
        "genomic_position":"17:41197646-41277500(-)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Resistance",
        "therapies":"Carboplatin + Olaparib + Paclitaxel + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05485766"
    },
    {
        "unnamed:_1":16,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"Amplification",
        "aa_mutation":"Amplification",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":17,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":18,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_WT1_unspecified",
        "aa_mutation":"unspecified_and_WT1_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":19,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_(PIK3CA_Exon9_or_PIK3CA_Exon20)_",
        "aa_mutation":"unspecified_and_(PIK3CA_Exon9_or_PIK3CA_Exon20)_",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":20,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_ESR1_unspecified",
        "aa_mutation":"unspecified_and_ESR1_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":21,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_GATA3_unspecified",
        "aa_mutation":"unspecified_and_GATA3_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":22,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_PIK3CA_unspecified",
        "aa_mutation":"unspecified_and_PIK3CA_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":23,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_PTEN_unspecified",
        "aa_mutation":"unspecified_and_PTEN_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":24,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_TBX3_unspecified",
        "aa_mutation":"unspecified_and_TBX3_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":25,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_TOP2A_unspecified",
        "aa_mutation":"unspecified_and_TOP2A_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":26,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_TP53_unspecified",
        "aa_mutation":"unspecified_and_TP53_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":27,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_TP53_unspecified_",
        "aa_mutation":"unspecified_and_TP53_unspecified_",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":28,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"Overexpression",
        "aa_mutation":"Overexpression",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":29,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"SERUM_LEVELS",
        "aa_mutation":"SERUM_LEVELS",
        "disease":"Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":30,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_ERBB2_unspecified",
        "aa_mutation":"unspecified_and_ERBB2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":31,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"Exon19,Exon20",
        "aa_mutation":"Exon19,Exon20",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":32,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":2,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":33,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":34,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"Amplification",
        "aa_mutation":"Amplification",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":35,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":36,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_NRG1_unspecified",
        "aa_mutation":"unspecified_and_NRG1_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":37,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_ERBB3_unspecified",
        "aa_mutation":"unspecified_and_ERBB3_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":38,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified_and_PIK3CA_unspecified",
        "aa_mutation":"unspecified_and_PIK3CA_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":39,
        "gene_name":"ERBB2",
        "genomic_position":"17:37856333-37884915(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma in situ | ductal carcinoma in situ",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"H2NVAC + Sargramostim",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04144023"
    },
    {
        "unnamed:_1":40,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Resistance",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":41,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":42,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"unspecified_or_PTEN_unspecified_or_TP53_unspecified",
        "aa_mutation":"unspecified_or_PTEN_unspecified_or_TP53_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":43,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":44,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"c.3140A>G",
        "aa_mutation":"p.H1047R",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":121913279.0,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":45,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Resistance",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":46,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":47,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"c.1634A>G",
        "aa_mutation":"p.E545",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":121913274.0,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":48,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"H1047X",
        "aa_mutation":"p.H1047X",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":49,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"c.1624G>A",
        "aa_mutation":"p.E542K",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":121913273.0,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":50,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"unspecified_or_PTEN_unspecified",
        "aa_mutation":"unspecified_or_PTEN_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":51,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":52,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":53,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"Exon9_or_PIK3CA_Exon20",
        "aa_mutation":"Exon9_or_PIK3CA_Exon20",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":54,
        "gene_name":"PIK3CA",
        "genomic_position":"3:178866311-178957881(+)",
        "cds_mutation":"c.3140A>G",
        "aa_mutation":"p.H1047R",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"Fulvestrant,Everolimus",
        "description":null,
        "rs_value":121913279.0,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":55,
        "gene_name":"AKT2",
        "genomic_position":"19:40736224-40791302(-)",
        "cds_mutation":"EXPRESSION",
        "aa_mutation":"EXPRESSION",
        "disease":"Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Trastuzumab",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:22842582"
    },
    {
        "unnamed:_1":56,
        "gene_name":"IGF1R",
        "genomic_position":"15:99192200-99507759(+)",
        "cds_mutation":"Overexpression",
        "aa_mutation":"Overexpression",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Metformin,Exemestane",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:26706833"
    },
    {
        "unnamed:_1":57,
        "gene_name":"TP53",
        "genomic_position":"17:7571720-7590856(-)",
        "cds_mutation":"c.745A>T",
        "aa_mutation":"p.R249",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Tamoxifen",
        "description":null,
        "rs_value":587782082.0,
        "pmid":"PubMed:10786679"
    },
    {
        "unnamed:_1":58,
        "gene_name":"TP53",
        "genomic_position":"17:7571720-7590856(-)",
        "cds_mutation":"DNA_Binding_Domain_Mutation",
        "aa_mutation":"DNA_Binding_Domain_Mutation",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Resistance",
        "therapies":"Tamoxifen",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:10786679"
    },
    {
        "unnamed:_1":59,
        "gene_name":"TP53",
        "genomic_position":"17:7571720-7590856(-)",
        "cds_mutation":"deletion_and_PDCD4_unspecified",
        "aa_mutation":"deletion_and_PDCD4_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Tamoxifen",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:10786679"
    },
    {
        "unnamed:_1":60,
        "gene_name":"TP53",
        "genomic_position":"17:7571720-7590856(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Tamoxifen",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:10786679"
    },
    {
        "unnamed:_1":61,
        "gene_name":"TP53",
        "genomic_position":"17:7571720-7590856(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Tamoxifen",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:10786679"
    },
    {
        "unnamed:_1":62,
        "gene_name":"TP53",
        "genomic_position":"17:7571720-7590856(-)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Breast Cancer",
        "therapy_rank":4,
        "response_to_drug":"Resistance",
        "therapies":"Tamoxifen",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:10786679"
    },
    {
        "unnamed:_1":63,
        "gene_name":"FGFR1",
        "genomic_position":"8:38268656-38325363(-)",
        "cds_mutation":"unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
        "aa_mutation":"unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"FGFR Inhibitor AZD4547",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27179038"
    },
    {
        "unnamed:_1":64,
        "gene_name":"FGFR1",
        "genomic_position":"8:38268656-38325363(-)",
        "cds_mutation":"Amplification",
        "aa_mutation":"Amplification",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"FGFR Inhibitor AZD4547",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27179038"
    },
    {
        "unnamed:_1":65,
        "gene_name":"FGFR1",
        "genomic_position":"8:38268656-38325363(-)",
        "cds_mutation":"unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
        "aa_mutation":"unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"FGFR Inhibitor AZD4547",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27179038"
    },
    {
        "unnamed:_1":66,
        "gene_name":"FGFR1",
        "genomic_position":"8:38268656-38325363(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"FGFR Inhibitor AZD4547",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27179038"
    },
    {
        "unnamed:_1":67,
        "gene_name":"FGFR1",
        "genomic_position":"8:38268656-38325363(-)",
        "cds_mutation":"unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
        "aa_mutation":"unspecified_or_FGFR2_unspecified_or_FGFR3_unspecified_or_FGFR4_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"FGFR Inhibitor AZD4547",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27179038"
    },
    {
        "unnamed:_1":68,
        "gene_name":"FGFR1",
        "genomic_position":"8:38268656-38325363(-)",
        "cds_mutation":"Amplification",
        "aa_mutation":"Amplification",
        "disease":"Breast Cancer",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"FGFR Inhibitor AZD4547",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27179038"
    },
    {
        "unnamed:_1":69,
        "gene_name":"ESR1",
        "genomic_position":"6:152011631-152424409(+)",
        "cds_mutation":"Overexpression",
        "aa_mutation":"Overexpression",
        "disease":"Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Endocrine therapy",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24217577"
    },
    {
        "unnamed:_1":70,
        "gene_name":"ESR1",
        "genomic_position":"6:152011631-152424409(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Endocrine therapy",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24217577"
    },
    {
        "unnamed:_1":71,
        "gene_name":"ESR1",
        "genomic_position":"6:152011631-152424409(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | ER-positive carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Endocrine therapy",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24217577"
    },
    {
        "unnamed:_1":72,
        "gene_name":"ESR1",
        "genomic_position":"6:152011631-152424409(+)",
        "cds_mutation":"c.851-26475A>G",
        "aa_mutation":"p.?",
        "disease":"ductal_carcinoma",
        "therapy_rank":1,
        "response_to_drug":"Resistance",
        "therapies":"Endocrine therapy",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24217577"
    },
    {
        "unnamed:_1":73,
        "gene_name":"ESR1",
        "genomic_position":"6:152011631-152424409(+)",
        "cds_mutation":"c.1613A>G",
        "aa_mutation":"p.D538G",
        "disease":"ductal_carcinoma",
        "therapy_rank":1,
        "response_to_drug":"Resistance",
        "therapies":"Endocrine therapy",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24217577"
    },
    {
        "unnamed:_1":74,
        "gene_name":"ESR1",
        "genomic_position":"6:152011631-152424409(+)",
        "cds_mutation":"c.830A>G",
        "aa_mutation":"p.D277G",
        "disease":"ductal_carcinoma",
        "therapy_rank":1,
        "response_to_drug":"Resistance",
        "therapies":"Endocrine therapy",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24217577"
    },
    {
        "unnamed:_1":75,
        "gene_name":"ESR1",
        "genomic_position":"6:152011631-152424409(+)",
        "cds_mutation":"c.*488A>G",
        "aa_mutation":"p.?",
        "disease":"ductal_carcinoma",
        "therapy_rank":1,
        "response_to_drug":"Resistance",
        "therapies":"Endocrine therapy",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:24217577"
    },
    {
        "unnamed:_1":76,
        "gene_name":"PTEN",
        "genomic_position":"10:89622870-89731687(+)",
        "cds_mutation":"Loss",
        "aa_mutation":"Loss",
        "disease":"Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Resistance",
        "therapies":"Everolimus,Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":77,
        "gene_name":"PTEN",
        "genomic_position":"10:89622870-89731687(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Everolimus,Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":78,
        "gene_name":"PTEN",
        "genomic_position":"10:89622870-89731687(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Everolimus,Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":79,
        "gene_name":"PTEN",
        "genomic_position":"10:89622870-89731687(+)",
        "cds_mutation":"Loss",
        "aa_mutation":"Loss",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Resistance",
        "therapies":"Everolimus,Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":80,
        "gene_name":"PTEN",
        "genomic_position":"10:89622870-89731687(+)",
        "cds_mutation":"Expression",
        "aa_mutation":"Expression",
        "disease":"Breast Cancer",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Everolimus,Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":81,
        "gene_name":"PTEN",
        "genomic_position":"10:89622870-89731687(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Everolimus,Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":82,
        "gene_name":"PTEN",
        "genomic_position":"10:89622870-89731687(+)",
        "cds_mutation":"Loss",
        "aa_mutation":"Loss",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Everolimus,Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":83,
        "gene_name":"PTEN",
        "genomic_position":"10:89622870-89731687(+)",
        "cds_mutation":"Expression",
        "aa_mutation":"Expression",
        "disease":"Her2-receptor Positive Breast Cancer",
        "therapy_rank":4,
        "response_to_drug":"Resistance",
        "therapies":"Everolimus,Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:27445490"
    },
    {
        "unnamed:_1":84,
        "gene_name":"AKT1",
        "genomic_position":"14:105235686-105260461(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Capivasertib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:26351323"
    },
    {
        "unnamed:_1":85,
        "gene_name":"AKT1",
        "genomic_position":"14:105235686-105260461(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capivasertib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:26351323"
    },
    {
        "unnamed:_1":86,
        "gene_name":"AKT1",
        "genomic_position":"14:105235686-105260461(-)",
        "cds_mutation":"unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "aa_mutation":"unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capivasertib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:26351323"
    },
    {
        "unnamed:_1":87,
        "gene_name":"AKT1",
        "genomic_position":"14:105235686-105260461(-)",
        "cds_mutation":"unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "aa_mutation":"unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capivasertib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:26351323"
    },
    {
        "unnamed:_1":88,
        "gene_name":"AKT1",
        "genomic_position":"14:105235686-105260461(-)",
        "cds_mutation":"c.49G>A",
        "aa_mutation":"p.E17K",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capivasertib",
        "description":null,
        "rs_value":121434592.0,
        "pmid":"PubMed:26351323"
    },
    {
        "unnamed:_1":89,
        "gene_name":"AKT1",
        "genomic_position":"14:105235686-105260461(-)",
        "cds_mutation":"unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "aa_mutation":"unspecified_or_ATM_unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_undefined_or_FANCD2_undefined_or_FANCE_undefined_or_FANCF_undefined_or_FANCG_undefined_or_FANCL_undefined_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PIK3CA_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capivasertib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:26351323"
    },
    {
        "unnamed:_1":90,
        "gene_name":"AKT1",
        "genomic_position":"14:105235686-105260461(-)",
        "cds_mutation":"c.49G>A",
        "aa_mutation":"p.E17K",
        "disease":"Breast Cancer",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"Capivasertib",
        "description":null,
        "rs_value":121434592.0,
        "pmid":"PubMed:26351323"
    },
    {
        "unnamed:_1":91,
        "gene_name":"BRCA2",
        "genomic_position":"13:32889617-32973805(+)",
        "cds_mutation":"unspecified_and_ERBB2_unspecified",
        "aa_mutation":"unspecified_and_ERBB2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    },
    {
        "unnamed:_1":92,
        "gene_name":"BRCA2",
        "genomic_position":"13:32889617-32973805(+)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Triple-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    },
    {
        "unnamed:_1":93,
        "gene_name":"BRCA2",
        "genomic_position":"13:32889617-32973805(+)",
        "cds_mutation":"Loss-of-function",
        "aa_mutation":"Loss-of-function",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    },
    {
        "unnamed:_1":94,
        "gene_name":"BRCA2",
        "genomic_position":"13:32889617-32973805(+)",
        "cds_mutation":"Loss-of-function",
        "aa_mutation":"Loss-of-function",
        "disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    },
    {
        "unnamed:_1":95,
        "gene_name":"BRCA2",
        "genomic_position":"13:32889617-32973805(+)",
        "cds_mutation":"Mutation",
        "aa_mutation":"Mutation",
        "disease":"Breast Cancer",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    },
    {
        "unnamed:_1":96,
        "gene_name":"BRCA2",
        "genomic_position":"13:32889617-32973805(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    },
    {
        "unnamed:_1":97,
        "gene_name":"ETV6",
        "genomic_position":"12:11802788-12048336(+)",
        "cds_mutation":"ETV6::NTRK3",
        "aa_mutation":"p.ETV6::NTRK3",
        "disease":"Breast Secretory Carcinoma",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"Larotrectinib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:29623306"
    },
    {
        "unnamed:_1":98,
        "gene_name":"CDKN2A",
        "genomic_position":"9:21968055-21974865(-)",
        "cds_mutation":"Loss",
        "aa_mutation":"Loss",
        "disease":"Her2-receptor Negative Breast Cancer",
        "therapy_rank":4,
        "response_to_drug":"Sensitivity",
        "therapies":"Letrozole,Palbociclib",
        "description":null,
        "rs_value":null,
        "pmid":"PubMed:26715889"
    },
    {
        "unnamed:_1":99,
        "gene_name":"BARD1",
        "genomic_position":"2:215590370-215674428(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Talazoparib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693"
    },
    {
        "unnamed:_1":100,
        "gene_name":"PPP2R2A",
        "genomic_position":"8:26150732-26228402(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Talazoparib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693"
    },
    {
        "unnamed:_1":101,
        "gene_name":"ERBB3",
        "genomic_position":"12:56473645-56497289(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Patritumab deruxtecan",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02980341"
    },
    {
        "unnamed:_1":102,
        "gene_name":"CHEK2",
        "genomic_position":"22:29083751-29137826(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    },
    {
        "unnamed:_1":103,
        "gene_name":"EGFR",
        "genomic_position":"7:55086794-55279321(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Gefitinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT01732276"
    },
    {
        "unnamed:_1":104,
        "gene_name":"EGFR",
        "genomic_position":"7:55086794-55279321(+)",
        "cds_mutation":"unspecified_and_ERBB2_unspecified",
        "aa_mutation":"unspecified_and_ERBB2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Gefitinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT01732276"
    },
    {
        "unnamed:_1":105,
        "gene_name":"EGFR",
        "genomic_position":"7:55086794-55279321(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Gefitinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT01732276"
    },
    {
        "unnamed:_1":106,
        "gene_name":"EGFR",
        "genomic_position":"7:55086794-55279321(+)",
        "cds_mutation":"unspecified_or_ERBB2_unspecified",
        "aa_mutation":"unspecified_or_ERBB2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Gefitinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT01732276"
    },
    {
        "unnamed:_1":107,
        "gene_name":"EGFR",
        "genomic_position":"7:55086794-55279321(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Gefitinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT01732276"
    },
    {
        "unnamed:_1":108,
        "gene_name":"ERBB4",
        "genomic_position":"2:212240446-213403565(-)",
        "cds_mutation":"unspecified_and_CD274_unspecified",
        "aa_mutation":"unspecified_and_CD274_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04872985"
    },
    {
        "unnamed:_1":109,
        "gene_name":"ERBB4",
        "genomic_position":"2:212240446-213403565(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04872985"
    },
    {
        "unnamed:_1":110,
        "gene_name":"ERBB4",
        "genomic_position":"2:212240446-213403565(-)",
        "cds_mutation":"unspecified_and_CD274_unspecified",
        "aa_mutation":"unspecified_and_CD274_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Cyclophosphamide + Docetaxel + Epirubicin hydrochloride + Nab-paclitaxel + Pyrotinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04872985"
    },
    {
        "unnamed:_1":111,
        "gene_name":"FGFR3",
        "genomic_position":"4:1795039-1810599(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Futibatinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04024436"
    },
    {
        "unnamed:_1":112,
        "gene_name":"BCL2",
        "genomic_position":"18:60790579-60987361(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Letrozole + Palbociclib + Venetoclax",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT03900884"
    },
    {
        "unnamed:_1":113,
        "gene_name":"ALK",
        "genomic_position":"2:29415640-30144432(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Crizotinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02034981"
    },
    {
        "unnamed:_1":114,
        "gene_name":"CDK12",
        "genomic_position":"17:37618292-37691399(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Talazoparib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693"
    },
    {
        "unnamed:_1":115,
        "gene_name":"MTOR",
        "genomic_position":"1:11166592-11322564(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Vistusertib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02299999"
    },
    {
        "unnamed:_1":116,
        "gene_name":"CD274",
        "genomic_position":"9:5450525-5470547(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Avelumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02926196"
    },
    {
        "unnamed:_1":117,
        "gene_name":"CD274",
        "genomic_position":"9:5450525-5470547(+)",
        "cds_mutation":"unspecified_and_ERBB2_unspecified",
        "aa_mutation":"unspecified_and_ERBB2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Avelumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02926196"
    },
    {
        "unnamed:_1":118,
        "gene_name":"CD274",
        "genomic_position":"9:5450525-5470547(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Avelumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02926196"
    },
    {
        "unnamed:_1":119,
        "gene_name":"CD274",
        "genomic_position":"9:5450525-5470547(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | basal (triple-negative) carcinoma",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Avelumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02926196"
    },
    {
        "unnamed:_1":120,
        "gene_name":"CD274",
        "genomic_position":"9:5450525-5470547(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Avelumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT02926196"
    },
    {
        "unnamed:_1":121,
        "gene_name":"RET",
        "genomic_position":"10:43572475-43625799(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Lenvatinib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT03168074"
    },
    {
        "unnamed:_1":122,
        "gene_name":"RAD51D",
        "genomic_position":"17:33427691-33446832(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    },
    {
        "unnamed:_1":123,
        "gene_name":"ROS1",
        "genomic_position":"6:117609463-117747018(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Crizotinib + Fulvestrant",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT03620643"
    },
    {
        "unnamed:_1":124,
        "gene_name":"NF1",
        "genomic_position":"17:29421945-29704695(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Famitinib + SHR7390",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858"
    },
    {
        "unnamed:_1":125,
        "gene_name":"KRAS",
        "genomic_position":"12:25362365-25403737(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Paclitaxel + Pelareorep",
        "description":null,
        "rs_value":null,
        "pmid":"Corporate website:NCT01656538"
    },
    {
        "unnamed:_1":126,
        "gene_name":"KRAS",
        "genomic_position":"12:25362365-25403737(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Paclitaxel + Pelareorep",
        "description":null,
        "rs_value":null,
        "pmid":"Corporate website:NCT01656538"
    },
    {
        "unnamed:_1":127,
        "gene_name":"PDGFRB",
        "genomic_position":"5:149493400-149535423(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Famitinb",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04355858"
    },
    {
        "unnamed:_1":128,
        "gene_name":"BRIP1",
        "genomic_position":"17:59758627-59940882(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Talazoparib",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04892693"
    },
    {
        "unnamed:_1":129,
        "gene_name":"ATM",
        "genomic_position":"11:108093559-108239826(+)",
        "cds_mutation":"unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
        "aa_mutation":"unspecified_or_ATR_unspecified_or_BAP1_unspecified_or_BARD1_unspecified_or_BLM_unspecified_or_BRIP1_unspecified_or_CHEK1_unspecified_or_CDK12_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_MRE11_unspecified_or_NBN_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_WRN_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":1,
        "response_to_drug":"Sensitivity",
        "therapies":"Olaparib + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756"
    },
    {
        "unnamed:_1":130,
        "gene_name":"ATM",
        "genomic_position":"11:108093559-108239826(+)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Olaparib + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756"
    },
    {
        "unnamed:_1":131,
        "gene_name":"ATM",
        "genomic_position":"11:108093559-108239826(+)",
        "cds_mutation":"unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "aa_mutation":"unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRCA1_unspecified_or_BRCA2_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCM_unspecified_or_MRE11A_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Olaparib + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756"
    },
    {
        "unnamed:_1":132,
        "gene_name":"ATM",
        "genomic_position":"11:108093559-108239826(+)",
        "cds_mutation":"unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
        "aa_mutation":"unspecified_or_ATR_unspecified_or_BARD1_unspecified_or_BRIP1_unspecified_or_CHEK2_unspecified_or_FANCA_unspecified_or_FANCC_unspecified_or_FANCD2_unspecified_or_FANCE_unspecified_or_FANCF_unspecified_or_FANCG_unspecified_or_FANCL_unspecified_or_MRE11_unspecified_or_NBN_unspecified_or_PALB2_unspecified_or_PTEN_unspecified_or_RAD50_unspecified_or_RAD51C_unspecified_RAD51D_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Olaparib + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756"
    },
    {
        "unnamed:_1":133,
        "gene_name":"ATM",
        "genomic_position":"11:108093559-108239826(+)",
        "cds_mutation":"unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
        "aa_mutation":"unspecified_or_BARD1_unspecified_or_CHEK2_unspecified_or_FANCC_unspecified_or_PALB2_unspecified_or_RAD51C_unspecified_or_RAD51D_unspecified_or_SLX4_unspecified_or_XRCC2_unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Olaparib + Pembrolizumab",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT05033756"
    },
    {
        "unnamed:_1":134,
        "gene_name":"PALB2",
        "genomic_position":"16:23614491-23652631(-)",
        "cds_mutation":"unspecified",
        "aa_mutation":"unspecified",
        "disease":"breast | carcinoma | NS",
        "therapy_rank":3,
        "response_to_drug":"Sensitivity",
        "therapies":"Capecitabine + Platinum-based chemotherapy",
        "description":null,
        "rs_value":null,
        "pmid":"ClinicalTrials.gov:NCT04335669"
    }
]